Institute for Biotechnology, St. John's University, New York, NY, 11439, USA; College of Pharmacy and Health Sciences, St. John's University, New York, NY, 11439, USA.
College of Pharmacy and Health Sciences, St. John's University, New York, NY, 11439, USA.
Cancer Lett. 2024 Aug 10;597:217061. doi: 10.1016/j.canlet.2024.217061. Epub 2024 Jun 13.
Hepatocellular carcinoma (HCC) is an increasingly prevalent disease that is associated with high and continually rising mortality rates. Lipid metabolism holds a crucial role in the pathogenesis of HCC, in which abnormalities pertaining to the delicate balance of lipid synthesis, breakdown, and storage, predispose for the pathogenesis of the nonalcoholic fatty liver disease (NAFLD), a disease precursor to HCC. If caught early enough, HCC treatment may be curative. In later stages, treatment is only halting the inevitable outcome of death, boldly prompting for novel drug discovery to provide a fighting chance for this patient population. In this review, we begin by providing a summary of current local and systemic treatments against HCC. From such we discuss hepatic lipid metabolism and highlight novel targets that are ripe for anti-cancer drug discovery. Lastly, we provide a targeted summary of current known risk factors for HCC pathogenesis, providing key insights that will be essential for rationalizing future development of anti-HCC therapeutics.
肝细胞癌 (HCC) 是一种日益流行的疾病，其死亡率高且持续上升。脂质代谢在 HCC 的发病机制中起着关键作用，其中脂质合成、分解和储存的微妙平衡异常，导致非酒精性脂肪性肝病 (NAFLD) 的发病，这是 HCC 的疾病前体。如果及早发现，HCC 的治疗可能是治愈性的。在晚期，治疗只是阻止死亡这一不可避免的结果，大胆地促使新的药物发现为这一患者群体提供一线生机。在这篇综述中，我们首先总结了目前针对 HCC 的局部和全身治疗方法。从这些方法中，我们讨论了肝脏脂质代谢，并强调了新的有希望的抗癌药物发现靶点。最后，我们对目前已知的 HCC 发病机制的风险因素进行了有针对性的总结，提供了对合理制定 HCC 治疗药物未来发展至关重要的关键见解。
